Loading
Sentiment · FY2026 Q2
As of FY2026 Q1, the Tellvest earnings-call sentiment score for Gilead Sciences (GILD) is 8/10.
Product sales grew 5% to $6.9 billion with non-GAAP EPS of $2.03 up 12% as the HIV treatment franchise sustained market leadership and YES2GO PrEP launch exceeded expectations. Management raised total product sales guidance to $30.0-$30.4 billion, a 1.3% midpoint increase driven by commercial outperformance. YES2GO's full-year target was increased to $1 billion, and strategic acquisitions expanded the pipeline across oncology platforms.
Scored from Gilead Sciences’s FY2026 Q1 earnings call. The newest quarter is available with Tellvest Pro.
Full Pro access for 30 days when you create a free account. No credit card required.
All prior quarters are free.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $7.57B | +6.4% | $1.42 | +24.6% | 79.1% | 32.4% | 23.6% | $2.83B |
| FY2025 Q1 | $6.67B | -0.3% | $1.04 | +131.1% | 76.9% | 33.6% | 19.7% | $1.65B |
| FY2025 Q2 | $7.08B | +1.8% | $1.56 | +20.9% | 78.8% | 34.9% | 27.7% | $720M |
| FY2025 Q3 | $7.77B | +3.0% | $2.43 | +143.0% | 79.8% | 42.8% | 39.3% | $3.96B |
| FY2025 Q4 | $7.92B | +4.7% | $1.74 | +22.5% | 79.5% | 37.7% | 27.5% | $3.12B |
| FY2026 Q1 | $6.96B | +4.4% | $1.61 | +54.8% | 79.2% | 37.2% | 29.0% | $2.43B |
| FY2026 Q2 | $7.80B | +10.2% | $-8.43 | -640.4% | — | -133.2% | -134.5% | $3.69B |